{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:56:33Z","timestamp":1790837793654,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CVP"],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Introduction: Stroke patients are at a higher risk of developing cognitive difficulties. Insulin\nresistance has been identified as a risk factor for decline in cognition, raising the possibility that\npioglitazone, an insulin-sensitizing agent, might benefit stroke patients with cognitive impairment by\nimproving insulin sensitivity.\n\nMethods: In this single-center, double-blind, randomized controlled trial, 131 eligible patients with\npost-stroke cognitive impairment were randomized to receive either standard therapy plus pioglitazone\n(15 mg once daily) or standard therapy alone plus matching placebo. Of the 131 randomized\nparticipants, 111 completed the study and were included in the per-protocol analysis.\n\nResults: No statistically significant between-group differences were observed for the primary outcomes,\nincluding the Montreal Cognitive Assessment (MoCA) score (p = 0.057), P300 latency (ms)\n(p = 0.64), P300 amplitude (\u03bcV) (p = 0.321), and plasma A\u03b242\/A\u03b240 ratio (p = 0.26). Furthermore,\n25 (45.5%) participants in the intervention arm and 13 (23.2%) participants in the control arm experienced\nat least one Adverse Drug Reaction (ADR) (p = 0.63).\n\nDiscussion: The study findings indicated that a low dose of pioglitazone did not significantly improve\ncognitive function over a 12-month period. The proposed neuroprotective effects of pioglitazone\nreported in previous studies were not reflected in the outcomes assessed in this trial.\n\nConclusion: Among stroke patients with cognitive impairment, pioglitazone as an add-on therapy\ndid not significantly improve cognitive function as measured by MoCA scores, P300 Event-Related\nPotentials (ERPs), and plasma amyloid-beta biomarkers over a 1-year period.\n\n(Clinical Trial number: CTRI2024\/09\/074281)\n\n(Date of registration: 24\/09\/2024)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115701611506984260923073428","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:11:03Z","timestamp":1790835063000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Pioglitazone in Improving Cognitive Function Among Stroke Patients: A Prospective, Double-Blind, Randomized Controlled Trial"],"prefix":"10.2174","volume":"24","author":[{"given":"Ian","family":"Osoro","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Instituteof Science and Technology, Kattankulathur- 603203, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Neurology, SRM Medical College Hospital and Research Centre, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur- 603203, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhasaparur Ganesan","family":"Rajanandh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Instituteof Science and Technology, Kattankulathur- 603203, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611506984260923073428","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258919\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611506984260923073428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:11:22Z","timestamp":1790835082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258919\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611506984260923073428","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}